HK Stock Market Move | MEDBOT-B(02252) rose more than 7% in early trading. Siasun Robot & Automation recently completed the world's first large model autonomous surgery animal experiment.

MEDBOT-B (02252) rose more than 7% in the early trading session, and as of the time of writing, it has risen by 5.7% to 26.7 Hong Kong dollars, with a turnover of 1.15 billion Hong Kong dollars. On the news front, Siasun Robot&Automation, a subsidiary of MicroGenius, announced recently that it has successfully completed the world's first "large model autonomous surgery" in live animal experiments using its independently developed "Neuron MicroGenius" multimodal autonomous surgery model. This achievement has no precedent in existing literature or medical practice, making it the first time in the world that the Siasun Robot&Automation has driven the surgery using a multimodal autonomous surgery model to complete key surgical steps in vivo in a process-level autonomous manner. It is worth noting that the company previously announced that, in terms of comprehensive orders, according to preliminary statistics within the Group, the combined order volume for the Group's core products in endoscopy, orthopedics, and vascular intervention has exceeded 230 units. Among them, the core product, the TUMI endoscopic surgery Siasun Robot&Automation (), has accumulated commercial orders of over 160 units globally, including nearly 120 new orders this year. According to public statistics, 's global order volume for 2025 has already ranked among the top two in the world.